公开(公告)号：US20220125807A1

公开(公告)日：2022-04-28

申请号：US17310756

申请日：2020-02-21

申请人： Max-Delbrück-Centrum für Molekulare Medizin in der Holmholtz-Gemeinschafft ,  Charité - Universitätsmedizin Berlin

发明人： Ulrike Stein ,  Dennis Kobelt ,  Benedikt Kortum ,  Harikrishnan Radhakrishnan ,  Wolfgang Walther

IPC分类号： A61K31/635 ,  A61K31/167 ,  A61K31/192 ,  A61K31/423 ,  A61K31/519 ,  A61K31/63 ,  A61K31/5415 ,  A61K31/40 ,  A61K31/366 ,  A61K31/405 ,  A61K31/47 ,  A61K31/22 ,  A61K31/505 ,  A61K31/4184 ,  A61K31/4523 ,  A61P35/00

摘要： A pharmaceutical combination, includes an inhibitor of the Wnt/β-catenin signaling pathway and an inhibitor of MACC1. One combination includes an inhibitor of S100A4 as a Wnt-signaling inhibitor, preferably niclosamide, and a statin or MEK1 inhibitor as an inhibitor of MACC1. A pharmaceutical composition can include the combination. The combination or composition can be used in the treatment of a tumor disease, such as a solid tumor, and/or for the treatment and/or prophylaxis of tumor metastasis.